The human ear is a delicate sensory apparatus of hearing for normal communication, and its proper functioning is highly dependent on mitochondrial oxidative phosphorylation. The first mitochondrial point mutation for ...The human ear is a delicate sensory apparatus of hearing for normal communication, and its proper functioning is highly dependent on mitochondrial oxidative phosphorylation. The first mitochondrial point mutation for nonsyndromic and aminoglycoside-induced hearing loss was identified in 1993. Since then a number of inherited mitochondrial mutations have been implicated in hearing loss. Most of the molecular defects responsible for mitochondrial disorder-associated hearing loss are mutations in the 12S rRNA gene and tRNA genes. In this review, after a short description of normal hearing mechanisms and mitochondrial genetics, we outline the recent advances that have been made in the identification of deafness-associated mitochondrial mutations, and discuss how mitochondrial dysfunction contributes to hearing loss.展开更多
Peginterferon and ribavirin combination therapy for the treatment of hepatitis C virus （HCV） is well known to be associated with significant adverse effects. Sensorineural hearing loss, that in most cases is unilate...Peginterferon and ribavirin combination therapy for the treatment of hepatitis C virus （HCV） is well known to be associated with significant adverse effects. Sensorineural hearing loss, that in most cases is unilateral, has been reported as a consequence of therapy with both non-pegylabed and pegylated interferon （pegIFN） but is not a well-known adverse effect. We report a 45-year-old Caucasian woman who developed acute sensorineural hearing loss 2 mo after starting therapy with pegIFN-α 2b and ribavirin for the treatment of chronic HCV, genotype la. She did not report the hearing loss to the hepatitis clinic until 1 mo, later whereupon therapy was promptly discontinued. Although her serum alanine aminotransferase （ALT） normalized and her HCV-RNA became undetectable after 12 wk of pegIFN and dbavirin therapy, after discontinuation, her HCV-RNA became detectable with significant elevations of serum ALT. Four months after initial discontinuation, the patient re-commenced pegIFN and ribavirin combination therapy. After 44 of 48 wk of therapy, the patient＇s liver biochemistry has normalized and the HCV-RNA is undetectable. She has not developed worsening of her hearing loss and hearing on the left-side is unaffected. Both patients and physicians should be aware that sensorineural hearing loss may occur with pegIFN therapy. Our experience suggests that re-institution of therapy is not always associated with further hearing impairment.展开更多
An acoustic pressure amplifier (APA) is capable of improving the match between a thermoacoustic engine and a load by elevating pressure ratio and acoustic power output. A standing-wave thermoacoustic engine driving a ...An acoustic pressure amplifier (APA) is capable of improving the match between a thermoacoustic engine and a load by elevating pressure ratio and acoustic power output. A standing-wave thermoacoustic engine driving a resistance- and-compliance (RC) load through an APA was simulated with linear thermoacoustics to study the impact of load impedance on the performance of the thermoacoustic system. Based on the simulation results, analysis focuses on the distribution of pressure amplitude and velocity amplitude in APA with an RC load of diverse acoustic resistances and compliance impedances. Variation of operating parameters, including pressure ratio, acoustic power, hot end temperature of stack, etc., versus impedance of the RC load is presented and analyzed according to the abovementioned distribution. A verifying experiment has been performed, which indicates that the simulation can roughly predict the system operation in the fundamental-frequency mode.展开更多
Let G be a second countable locally compact groupoid with Haar system {λu}, H be a closed subgroupoid containing Go with Haar system {λuH}. T.Masuda introduced the C*-Groupoid dynamic system (G, A, α) and its reduc...Let G be a second countable locally compact groupoid with Haar system {λu}, H be a closed subgroupoid containing Go with Haar system {λuH}. T.Masuda introduced the C*-Groupoid dynamic system (G, A, α) and its reduced crossed product Cr.d(G, A) in [2], where A is a C*-algebra, α is the homomorphism G→Aut(A). In this paper the author introduces the C*-groupoid dynamic systems (H, A, α|H) and (H\G2, A, α) induced by (G, A, α) and proves that C~*red(H, A) and C~*red(H\G2, A) are strongly Morita equivalent. Moreover the induced representation from C~*red(H, A) to C~*red(G, A) is got.展开更多
基金We acknowledge the support by a grant award from Jiangsu Natural Science Foundation,Grant No.BK2006247grant awards from Jiangsu Health Administration,Grant No.WK0623 and K200502.
文摘The human ear is a delicate sensory apparatus of hearing for normal communication, and its proper functioning is highly dependent on mitochondrial oxidative phosphorylation. The first mitochondrial point mutation for nonsyndromic and aminoglycoside-induced hearing loss was identified in 1993. Since then a number of inherited mitochondrial mutations have been implicated in hearing loss. Most of the molecular defects responsible for mitochondrial disorder-associated hearing loss are mutations in the 12S rRNA gene and tRNA genes. In this review, after a short description of normal hearing mechanisms and mitochondrial genetics, we outline the recent advances that have been made in the identification of deafness-associated mitochondrial mutations, and discuss how mitochondrial dysfunction contributes to hearing loss.
文摘Peginterferon and ribavirin combination therapy for the treatment of hepatitis C virus （HCV） is well known to be associated with significant adverse effects. Sensorineural hearing loss, that in most cases is unilateral, has been reported as a consequence of therapy with both non-pegylabed and pegylated interferon （pegIFN） but is not a well-known adverse effect. We report a 45-year-old Caucasian woman who developed acute sensorineural hearing loss 2 mo after starting therapy with pegIFN-α 2b and ribavirin for the treatment of chronic HCV, genotype la. She did not report the hearing loss to the hepatitis clinic until 1 mo, later whereupon therapy was promptly discontinued. Although her serum alanine aminotransferase （ALT） normalized and her HCV-RNA became undetectable after 12 wk of pegIFN and dbavirin therapy, after discontinuation, her HCV-RNA became detectable with significant elevations of serum ALT. Four months after initial discontinuation, the patient re-commenced pegIFN and ribavirin combination therapy. After 44 of 48 wk of therapy, the patient＇s liver biochemistry has normalized and the HCV-RNA is undetectable. She has not developed worsening of her hearing loss and hearing on the left-side is unaffected. Both patients and physicians should be aware that sensorineural hearing loss may occur with pegIFN therapy. Our experience suggests that re-institution of therapy is not always associated with further hearing impairment.
基金Project supported by the National Natural Sciences Foundation of China (No. 50536040)the University Doctoral Subject Special Foundation of China (No. 20050335047)+1 种基金the Postdoctoral Science Foundation of Zhejiang Province (No. 2006-bsh-21)the Natural Science Foundation of Zhejiang Province (No. Y107229), China
文摘An acoustic pressure amplifier (APA) is capable of improving the match between a thermoacoustic engine and a load by elevating pressure ratio and acoustic power output. A standing-wave thermoacoustic engine driving a resistance- and-compliance (RC) load through an APA was simulated with linear thermoacoustics to study the impact of load impedance on the performance of the thermoacoustic system. Based on the simulation results, analysis focuses on the distribution of pressure amplitude and velocity amplitude in APA with an RC load of diverse acoustic resistances and compliance impedances. Variation of operating parameters, including pressure ratio, acoustic power, hot end temperature of stack, etc., versus impedance of the RC load is presented and analyzed according to the abovementioned distribution. A verifying experiment has been performed, which indicates that the simulation can roughly predict the system operation in the fundamental-frequency mode.
文摘Let G be a second countable locally compact groupoid with Haar system {λu}, H be a closed subgroupoid containing Go with Haar system {λuH}. T.Masuda introduced the C*-Groupoid dynamic system (G, A, α) and its reduced crossed product Cr.d(G, A) in [2], where A is a C*-algebra, α is the homomorphism G→Aut(A). In this paper the author introduces the C*-groupoid dynamic systems (H, A, α|H) and (H\G2, A, α) induced by (G, A, α) and proves that C~*red(H, A) and C~*red(H\G2, A) are strongly Morita equivalent. Moreover the induced representation from C~*red(H, A) to C~*red(G, A) is got.
